Share

|

|

|

VTE rates not significantly reduced by apixaban in paediatric ALL or lymphoma

Apixaban does not significantly reduce the rate of venous thromboembolism relative to standard care in paediatric patients with acute lymphoblastic leukaemia or lymphoma, show data from the phase 3 PREVAPIX-ALL trial.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Upfront dabrafenib plus trametinib supported for paediatric low-grade glioma

First-line treatment with dabrafenib plus trametinib is significantly more likely to achieve a response than chemotherapy for children with low-grade glioma carrying a BRAF V600 alteration, indicates a phase 2 trial.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.